Disclaimer: The information, documents and graphic depictions (the "Information") published on this Web site are the property of LIfT BioSciences Ltd. LIfT BioSciences assumes no responsibility for errors or omissions in the Information on this website. In no event shall LIfT BioSciences be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of this Web site or the Information. LIfT BioSciences reserves the right to make additions, deletions, or modification to the Information on the Web site at any time without prior notice.

  • CEO's Linked-in
  • CEO's Twitter
  • LIfTBio on Facebook

©2016 LIfT BioSciences Ltd

OUR ADVISORY BOARD

Professor Farzin Farzaneh

DPhil, FRCPath, FRSB

Scientific Advisor & Research Partner

Expert in Molecular Medicine and Cell Therapies at King’s College London, whose Cell therapy Unit offers one of the most advanced GMP Cell Production facilities in Europe. Experienced in running GMP facilities for the production of cell and gene therapy based investigational medicinal products since 2001

Dr Jonathan Milner

PhD

Funding & Growth Advisor

Jonathan Milner, co-founder and currently Deputy Chairman of Abcam plc, is an experienced entrepreneur and investor and is passionate about supporting UK healthcare and high-tech start-ups.  He has provided considerable investment to LIfT BioSciences, and intends to help LIfT BioSciences get N-LIfT to market and to secure a successful exit. Jonathan already helped three tech companies IPO on AIM.

Dr Tony de Fougerolles

PhD

Scientific & Partnerships Advisor

Successful Biotech entrepreneur with a strong background in successfully developing and advancing multiple different transformative therapeutic drug platforms in both the nucleic acid and biologics space. In addition, his in-depth expertise in drug development has led to the progression of multiple assets through clinical trials. Prior to joining Evox Therapeutics, Tony was CSO at Ablynx NV and Moderna Therapeutics, and VP Research at Alnylam Pharmaceuticals. PhD in Immunology from Harvard University.

Prof James Spicer

MRCP, PhD, FCRP

Principle Investigator & Clinical Advisor

Professor of Experimental Cancer Medicine, King’s College London, and Consultant in Medical Oncology, Guy’s and St. Thomas’ Hospitals London. He holds a PhD in Cancer Biology from the Institute of Cancer Research in London, and a degree in biochemistry from the University of Oxford. Our Principle Investigator for our planned PoC trial.

Ali Stunt

Patient Interests Advisor

Founder & CEO of Pancreatic Cancer Action, Founding Board Member and Awareness Group Lead for Pancreatic Cancer Europe. Ali is herself a rare survivor of Pancreatic Cancer.